cytotoxic T-lymphocyte antigen-4

cytotoxic T-lymphocyte antigen-4 (CTLA-4),

expressed by activated T cells. When synthesized as a soluble molecule fused to the Fc of IgG, it is used as a biologic therapy in rhematic diseases, because it blocks a costimulatory molecule on B lymphocytes.
Farlex Partner Medical Dictionary © Farlex 2012
Mentioned in ?
References in periodicals archive ?
According to the company, AGEN1884 is an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Agenus' anti-CTLA-4 and anti-GITR Antibodies IND passes US FDA clearance
Cytotoxic T-lymphocyte antigen-4 (CTLA-4): a negative feedback mechanism that limits the body's developing immune response to keep it from becoming overactivated and causing nonspecific damage
Address the nursing challenges associated with treatment for advanced melanoma: as seen in the Clinical Journal of Oncology Nursing and Oncology Nursing Forum
Urba, "Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies," Cancer, vol.
Immunotherapies: Exploiting the Immune System for Cancer Treatment

Medical browser ?
Full browser ?